Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study

[1]  J. Witztum,et al.  Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis , 2000, Journal of internal medicine.

[2]  C. Napoli,et al.  Lipoprotein modification and atherosclerosis in aging , 1999, Experimental Gerontology.

[3]  C. Napoli,et al.  Intracranial arteries of human fetuses are more resistant to hypercholesterolemia-induced fatty streak formation than extracranial arteries. , 1999, Circulation.

[4]  C. Martyn,et al.  Impaired fetal growth and atherosclerosis of carotid and peripheral arteries , 1998, The Lancet.

[5]  C. Glass,et al.  Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein , 1998 .

[6]  J. Borén,et al.  Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding. , 1998, The Journal of clinical investigation.

[7]  R. Tracy,et al.  Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. , 1998, The New England journal of medicine.

[8]  M. Kilby,et al.  Fetal and maternal lipoprotein metabolism in human pregnancy complicated by type I diabetes mellitus. , 1998, The Journal of clinical endocrinology and metabolism.

[9]  A. von Eckardstein,et al.  Phenotype-dependent differences in apolipoprotein E metabolism and in cholesterol homeostasis in human monocyte-derived macrophages. , 1998, The Journal of clinical investigation.

[10]  T. Finkel.  Oxygen radicals and signaling. , 1998, Current opinion in cell biology.

[11]  J L Witztum,et al.  Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. , 1997, The Journal of clinical investigation.

[12]  I. White,et al.  Can dietary interventions change diet and cardiovascular risk factors? A meta-analysis of randomized controlled trials. , 1997, American journal of public health.

[13]  C. Hennekens,et al.  Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. , 1997, JAMA.

[14]  C. Napoli,et al.  Decreased low-density lipoprotein oxidation after repeated selective apheresis in homozygous familial hypercholesterolemia. , 1997, American heart journal.

[15]  S A Stansfeld,et al.  Low job control and risk of coronary heart disease in whitehall ii (prospective cohort) study , 1997, BMJ.

[16]  M. Kramer,et al.  Enigma of fetal/infant-origins hypothesis , 1996, The Lancet.

[17]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[18]  E. Arnesen,et al.  Pregnancy related changes in some cardiovascular risk factors , 1996, Acta obstetricia et gynecologica Scandinavica.

[19]  F. Kelly,et al.  Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) , 1996, The Lancet.

[20]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[21]  C. Furberg,et al.  Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. , 1995, Circulation.

[22]  P. Edwards,et al.  Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. , 1995, Circulation.

[23]  P. Poole‐Wilson,et al.  Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. , 1994, European heart journal.

[24]  W D Wagner,et al.  A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[25]  H. Hodis,et al.  George Lyman Duff Memorial Lecture. Arterial imaging and atherosclerosis reversal. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[26]  J. Mckenney,et al.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.

[27]  D. Harrison,et al.  Hypercholesterolemia increases endothelial superoxide anion production. , 1993, The Journal of clinical investigation.

[28]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[29]  Ncep Expert Panel on Blood Cholesterol Levels in Childr Adolescents.  National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. , 1992, Pediatrics.

[30]  D. Steinberg,et al.  Role of oxidized low density lipoprotein in atherogenesis. , 1991, The Journal of clinical investigation.

[31]  S. Aaronson,et al.  Growth factors and cancer. , 1991, Science.

[32]  J L Witztum,et al.  Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. , 1990, Arteriosclerosis.

[33]  D. Barker,et al.  WEIGHT IN INFANCY AND DEATH FROM ISCHAEMIC HEART DISEASE , 1989, The Lancet.

[34]  B. Paigen,et al.  Ath-2, a second gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. , 1989, Genetics.

[35]  J L Witztum,et al.  Low density lipoprotein undergoes oxidative modification in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Dietschy,et al.  Sterol synthesis and low density lipoprotein clearance in vivo in the pregnant rat, placenta, and fetus. Sources for tissue cholesterol during fetal development. , 1988, The Journal of clinical investigation.

[37]  A. Harris,et al.  Carboplatin/cisplatin , 2012, Reactions Weekly.

[38]  A. Lusis,et al.  Ath-1, a gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[39]  A. Gown,et al.  Human atherosclerosis. II. Immunocytochemical analysis of the cellular composition of human atherosclerotic lesions. , 1986, The American journal of pathology.

[40]  M. Brown,et al.  A receptor-mediated pathway for cholesterol homeostasis. , 1986, Science.

[41]  J. Albers,et al.  Physiologic and Supraphysiologic Increases in Lipoprotein Lipids and Apoproteins in Late Pregnancy and Postpartum: Possible Markers for the Diagnosis of “Prelipemia” , 1984, Arteriosclerosis.

[42]  W. Connor,et al.  The effects of dietary cholesterol upon the hypercholesterolemia of pregnancy. , 1981, Metabolism: clinical and experimental.

[43]  C. Napoli,et al.  Effects of vitamin E and HMG‐CoA reductase inhibition on cholesteryl ester transfer protein and lecithin‐cholesterol acyltransferase in hypercholesterolemia , 1998, Coronary artery disease.

[44]  H. Hodis,et al.  Arterial imaging and atherosclerosis reversal , 1994 .

[45]  Multifactorial Etiology,et al.  George Lyman Duff Memorial Lecture , 1991 .